{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:51:42Z","timestamp":1792741902569,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11102-021-01141-8","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T14:03:47Z","timestamp":1616594627000},"page":"630-643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1985","authenticated-orcid":false,"given":"Pedro","family":"Iglesias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Crist\u00f3bal","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"1141_CR1","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","volume":"19","author":"PA Ott","year":"2013","unstructured":"Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300\u20135309","journal-title":"Clin Cancer Res"},{"key":"1141_CR2","first-page":"605478","volume":"2015","author":"A Ito","year":"2015","unstructured":"Ito A, Kondo S, Tada K, Kitano S (2015) Clinical development of immune checkpoint inhibitors. Biomed Res Int 2015:605478","journal-title":"Biomed Res Int"},{"key":"1141_CR3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"1141_CR4","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455\u20132465","journal-title":"N Engl J Med"},{"key":"1141_CR5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","volume":"19","author":"F Conforti","year":"2018","unstructured":"Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A (2018) Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis. Lancet Oncol 19:737\u2013746","journal-title":"Lancet Oncol"},{"key":"1141_CR6","doi-asserted-by":"crossref","unstructured":"Johnson DB, Jakubovic BD, Sibaud V, Sise ME (2020) Balancing cancer immunotherapy efficacy and toxicity. J Allergy Clin Immunol Pract","DOI":"10.1016\/j.jaip.2020.06.028"},{"key":"1141_CR7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.medcli.2015.02.010","volume":"145","author":"P Iglesias","year":"2015","unstructured":"Iglesias P, Soria A, Diez JJ (2015) Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer. Med Clin (Barc) 145:264\u2013268","journal-title":"Med Clin (Barc)"},{"key":"1141_CR8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","volume":"47","author":"P Iglesias","year":"2018","unstructured":"Iglesias P (2018) Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach. Eur J Intern Med 47:6\u201313","journal-title":"Eur J Intern Med"},{"key":"1141_CR9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1507\/endocrj.EJ16-0161","volume":"63","author":"Y Okano","year":"2016","unstructured":"Okano Y, Satoh T, Horiguchi K, Toyoda M, Osaki A, Matsumoto S, Tomaru T, Nakajima Y, Ishii S, Ozawa A, Shibusawa N, Shimada T, Higuchi T, Chikamatsu K, Yamada M (2016) Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J 63:905\u2013912","journal-title":"Endocr J"},{"key":"1141_CR10","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/1346-8138.13532","volume":"44","author":"T Fujimura","year":"2017","unstructured":"Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Hidaka T, Haga T, Hashimoto A, Morimoto R, Aiba S (2017) Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient. J Dermatol 44:e13\u2013e14","journal-title":"J Dermatol"},{"key":"1141_CR11","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2169\/internalmedicine.8548-16","volume":"56","author":"K Takaya","year":"2017","unstructured":"Takaya K, Sonoda M, Fuchigami A, Hiyoshi T (2017) Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. Intern Med 56:2463\u20132469","journal-title":"Intern Med"},{"key":"1141_CR12","doi-asserted-by":"crossref","first-page":"e8426","DOI":"10.1097\/MD.0000000000008426","volume":"96","author":"MF Zeng","year":"2017","unstructured":"Zeng MF, Chen LL, Ye HY, Gong W, Zhou LN, Li YM, Zhao XL (2017) Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: Case report and review. Medicine (Baltimore) 96:e8426","journal-title":"Medicine (Baltimore)"},{"key":"1141_CR13","doi-asserted-by":"crossref","unstructured":"Kastrisiou M, Kostadima FL, Kefas A, Zarkavelis G, Kapodistrias N, Ntouvelis E, Petrakis D, Papadaki A, Vassou A, Pentheroudakis G (2017) Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. ESMO Open 2:e000217\u20132017\u2013000217. eCollection 2017","DOI":"10.1136\/esmoopen-2017-000217"},{"key":"1141_CR14","first-page":"115","volume":"42","author":"T Seki","year":"2017","unstructured":"Seki T, Yasuda A, Oki M, Kitajima N, Takagi A, Nakajima N, Miyajima A, Fukagawa M (2017) Secondary adrenal insufficiency following Nivolumab therapy in a patient with metastatic renal cell carcinoma. Tokai J Exp Clin Med 42:115\u2013120","journal-title":"Tokai J Exp Clin Med"},{"issue":"e70\u20138138","key":"1141_CR15","first-page":"13571","volume":"44","author":"A Narahira","year":"2017","unstructured":"Narahira A, Yanagi T, Cho KY, Nakamura A, Miyoshi H, Hata H, Imafuku K, Kitamura S, Shimizu H (2017) Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy. J Dermatol 44(e70\u20138138):13571 (Epub 2016 Sep 8)","journal-title":"J Dermatol"},{"key":"1141_CR16","doi-asserted-by":"crossref","unstructured":"Ariyasu H, Inaba H, Ota T, Yamaoka H, Furukawa Y, Iwakura H, Doi N, Yamamoto Y, Akamizu T (2018) Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma. In Vivo 32:345\u2013351","DOI":"10.21873\/invivo.11244"},{"key":"1141_CR17","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jtho.2017.10.023","volume":"13","author":"A Boudjemaa","year":"2018","unstructured":"Boudjemaa A, Rousseau-Bussac G, Monnet I (2018) Late-onset adrenal insufficiency more than 1 year after stopping Pembrolizumab. J Thorac Oncol 13:e39\u2013e40","journal-title":"J Thorac Oncol"},{"key":"1141_CR18","doi-asserted-by":"crossref","unstructured":"Oristrell G, Baneras J, Ros J, Munoz E (2018) Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report. Eur Heart J Case Rep 2:yty038","DOI":"10.1093\/ehjcr\/yty038"},{"key":"1141_CR19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.14740\/jocmr3257w","volume":"10","author":"K Takebayashi","year":"2018","unstructured":"Takebayashi K, Ujiie A, Kubo M, Furukawa S, Yamauchi M, Shinozaki H, Suzuki T, Naruse R, Hara K, Tsuchiya T, Inukai T (2018) Isolated adrenocorticotropic hormone deficiency and severe hypercalcemia after destructive thyroiditis in a patient on Nivolumab therapy with a malignant Melanoma. J Clin Med Res 10:358\u2013362","journal-title":"J Clin Med Res"},{"key":"1141_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-225048","author":"S Shrotriya","year":"2018","unstructured":"Shrotriya S, Rai MP, Alratroot A, Sarzynski E (2018) Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC). BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2018-225048","journal-title":"BMJ Case Rep"},{"key":"1141_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-230848","author":"J Pierrard","year":"2019","unstructured":"Pierrard J, Petit B, Lejeune S, Seront E (2019) Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barre syndrome occurring in a patient treated with nivolumab. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2019-230848","journal-title":"BMJ Case Rep"},{"key":"1141_CR22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.12659\/AJCR.913021","volume":"20","author":"C Sakaguchi","year":"2019","unstructured":"Sakaguchi C, Yano S, Ashida K, Wada N, Ohe K, Nagata H, Matsuda Y, Sakamoto S, Sakamoto R, Ohnaka K, Uchi H, Furue M, Nomura M, Ogawa Y (2019) A case of acute exacerbation of chronic adrenal insufficiency due to Ipilimumab treatment for advanced melanoma. Am J Case Rep 20:106\u2013110","journal-title":"Am J Case Rep"},{"key":"1141_CR23","first-page":"304","volume":"10","author":"N Furubayashi","year":"2019","unstructured":"Furubayashi N, Negishi T, Uozumi T, Takamatsu D, Shiraishi K, Hirose D, Nakamura M (2019) Isolated adrenocorticotropic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: A case report. Mol Clin Oncol 10:304\u2013308","journal-title":"Mol Clin Oncol"},{"key":"1141_CR24","first-page":"223","volume":"26","author":"Y Sato","year":"2019","unstructured":"Sato Y, Tanaka Y, Hino M, Seike M, Gemma A (2019) A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency. Respir Med Case Rep 26:223\u2013226","journal-title":"Respir Med Case Rep"},{"key":"1141_CR25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.anl.2019.02.005","volume":"46","author":"K Hihara","year":"2019","unstructured":"Hihara K, Sato H, Okamoto I, Katsube Y, Maruyama R, Tomioka R, Tanaka H, Tsukahara K (2019) Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer. Auris Nasus Larynx 46:896\u2013901","journal-title":"Auris Nasus Larynx"},{"key":"1141_CR26","doi-asserted-by":"crossref","unstructured":"Ohara N, Kobayashi M, Ohashi K, Ito R, Ikeda Y, Kawaguchi G, Yoneoka Y, Hasegawa G, Takada T (2019) Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature. J Med Case Rep 13:88\u2013019\u20132002\u20132","DOI":"10.1186\/s13256-019-2002-2"},{"key":"1141_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231236","author":"C Martins Machado","year":"2019","unstructured":"Martins Machado C, Almeida Santos L, Barroso A, Oliveira MJ (2019) Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2019-231236","journal-title":"BMJ Case Rep"},{"key":"1141_CR28","doi-asserted-by":"crossref","unstructured":"Takeno A, Yamamoto M, Morita M, Tanaka S, Kanazawa I, Yamauchi M, Kaneko S, Sugimoto T (2019) Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report. BMC Endocr Disord 19:25\u2013019\u20130335-x","DOI":"10.1186\/s12902-019-0335-x"},{"key":"1141_CR29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1507\/endocrj.EJ18-0328","volume":"66","author":"S Okahata","year":"2019","unstructured":"Okahata S, Sakamoto K, Mitsumatsu T, Kondo Y, Noso S, Ikegami H, Shiba T (2019) Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy. Endocr J 66:295\u2013300","journal-title":"Endocr J"},{"key":"1141_CR30","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0102","author":"I Lupi","year":"2019","unstructured":"Lupi I, Brancatella A, Cosottini M, Viola N, Lanzolla G, Sgro D, Dalmazi GD, Latrofa F, Caturegli P, Marcocci C (2019) Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/EDM-19-0102","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"1141_CR31","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.2169\/internalmedicine.3008-19","volume":"58","author":"S Yamagata","year":"2019","unstructured":"Yamagata S, Kageyama K, Takayasu S, Asari Y, Makita K, Terui K, Daimon M (2019) Progression of hypopituitarism and hypothyroidism after treatment with pembrolizumab in a patient with adrenal metastasis from non-small-cell lung cancer. Intern Med 58:3557\u20133562","journal-title":"Intern Med"},{"key":"1141_CR32","doi-asserted-by":"crossref","unstructured":"Tanaka S, Kushimoto M, Nishizawa T, Takubo M, Mitsuke K, Ikeda J, Fujishiro M, Ogawa K, Tsujino I, Suzuki Y, Abe M (2020) Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report. Clin Diabetes Endocrinol 6:1\u2013019\u20130092\u20139. eCollection 2020","DOI":"10.1186\/s40842-019-0092-9"},{"key":"1141_CR33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anl.2019.05.009","volume":"47","author":"H Kagoshima","year":"2020","unstructured":"Kagoshima H, Hori R, Kojima T, Okanoue Y, Fujimura S, Taguchi A, Shoji K (2020) Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer. Auris Nasus Larynx 47:309\u2013313","journal-title":"Auris Nasus Larynx"},{"key":"1141_CR34","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jjco\/hyx018","volume":"47","author":"K Kitajima","year":"2017","unstructured":"Kitajima K, Ashida K, Wada N, Suetsugu R, Takeichi Y, Sakamoto S, Uchi H, Matsushima T, Shiratsuchi M, Ohnaka K, Furue M, Nomura M (2017) Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. Jpn J Clin Oncol 47:463\u2013466","journal-title":"Jpn J Clin Oncol"},{"key":"1141_CR35","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1093\/annonc\/mdx497","volume":"28","author":"K Otsubo","year":"2017","unstructured":"Otsubo K, Nakatomi K, Furukawa R, Ashida K, Yoneshima Y, Nakanishi Y, Okamoto I (2017) Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. Ann Oncol 28:3106\u20133107","journal-title":"Ann Oncol"},{"key":"1141_CR36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1507\/endocrj.EJ16-0596","volume":"64","author":"KY Cho","year":"2017","unstructured":"Cho KY, Miyoshi H, Nakamura A, Kurita T, Atsumi T (2017) Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor. Endocr J 64:235\u2013236","journal-title":"Endocr J"},{"key":"1141_CR37","first-page":"4229","volume":"37","author":"R Ariyasu","year":"2017","unstructured":"Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Nishio M (2017) Adrenal insufficiency related to anti-programmed death-1 therapy. Anticancer Res 37:4229\u20134232","journal-title":"Anticancer Res"},{"key":"1141_CR38","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/ccr3.1567","volume":"6","author":"M Nagasaka","year":"2018","unstructured":"Nagasaka M, Abdallah N, Samantray J, Sukari A (2018) Is this really just \u201cfatigue\u201d? A case series of immune-related central adrenal insufficiency secondary to immune checkpoint inhibitors. Clin Case Rep 6:1278\u20131281","journal-title":"Clin Case Rep"},{"key":"1141_CR39","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2340\/00015555-2902","volume":"98","author":"S Kitano","year":"2018","unstructured":"Kitano S, Tatsuno K, Ishibe J, Shimauchi T, Fujiyama T, Ito T, Ogawa N, Tokura Y (2018) Isolated adrenocorticotropic hormone deficiency in melanoma patients treated with Nivolumab. Acta Derm Venereol 98:704\u2013705","journal-title":"Acta Derm Venereol"},{"key":"1141_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000779","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Fujimoto Y, Hibi H, Sone M, Ando Y, Akiyama M, Hasegawa Y, Arima H (2020) Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000779","journal-title":"J Immunother Cancer"},{"key":"1141_CR41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/CJI.0000000000000299","volume":"43","author":"K Suzuki","year":"2020","unstructured":"Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M (2020) Nivolumab-induced adrenal insufficiency in patients with renal cell carcinoma. J Immunother 43:38\u201342","journal-title":"J Immunother"},{"key":"1141_CR42","doi-asserted-by":"crossref","first-page":"102454","DOI":"10.1016\/j.autrev.2019.102454","volume":"19","author":"R Percik","year":"2020","unstructured":"Percik R, Shlomai G, Tirosh A, Tirosh A, Leibowitz-Amit R, Eshet Y, Greenberg G, Merlinsky A, Barhod E, Steinberg-Silman Y, Sella T (2020) Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. Autoimmun Rev 19:102454","journal-title":"Autoimmun Rev"},{"key":"1141_CR43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000505687","volume":"13","author":"T Bekki","year":"2020","unstructured":"Bekki T, Takakura Y, Kochi M, Konemori Y, Oki K, Yoneda M, Egi H, Ohdan H (2020) A case of isolated adrenocorticotropic hormone deficiency caused by Pembrolizumab. Case Rep Oncol 13:200\u2013206","journal-title":"Case Rep Oncol"},{"key":"1141_CR44","first-page":"e7625","volume":"12","author":"M Rai","year":"2020","unstructured":"Rai M, Go M (2020) Nivolumab induced adrenal insufficiency: rare side-effect of a new anti-cancer therapy\u2014immune-checkpoint inhibitors. Cureus 12:e7625","journal-title":"Cureus"},{"key":"1141_CR45","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-34","journal-title":"J Clin Epidemiol"},{"key":"1141_CR46","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, Samuels MH (2016) Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:3888\u20133921","journal-title":"J Clin Endocrinol Metab"},{"key":"1141_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","volume":"167","author":"A Juszczak","year":"2012","unstructured":"Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB (2012) Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1\u20135","journal-title":"Eur J Endocrinol"},{"key":"1141_CR48","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99:4078\u20134085","journal-title":"J Clin Endocrinol Metab"},{"key":"1141_CR49","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19:82\u201392","journal-title":"Pituitary"},{"key":"1141_CR50","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/EJE-19-0169","volume":"181","author":"F Albarel","year":"2019","unstructured":"Albarel F, Castinetti F, Brue T (2019) MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis. Eur J Endocrinol 181:R107\u2013R118","journal-title":"Eur J Endocrinol"},{"key":"1141_CR51","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1002\/cam4.2661","volume":"8","author":"J Lu","year":"2019","unstructured":"Lu J, Li L, Lan Y, Liang Y, Meng H (2019) Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. Cancer Med 8:7503\u20137515","journal-title":"Cancer Med"},{"key":"1141_CR52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173\u2013182","journal-title":"JAMA Oncol"},{"key":"1141_CR53","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.3390\/jcm9103280","volume":"9","author":"M Levy","year":"2020","unstructured":"Levy M, Abeillon J, Dalle S, Assaad S, Borson-Chazot F, Disse E, Raverot G, Cugnet-Anceau C (2020) Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up. J Clin Med 9:3280. https:\/\/doi.org\/10.3390\/jcm9103280","journal-title":"J Clin Med"},{"key":"1141_CR54","doi-asserted-by":"crossref","unstructured":"Steinberg A, Shechter FR, Segal HI (1954) True pituitary Addison's disease, a pituitary unitropic deficiency; fifteen-year follow-up. J Clin Endocrinol Metab 14:1519\u20131529","DOI":"10.1210\/jcem-14-12-1519"},{"key":"1141_CR55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11102-006-0408-5","volume":"9","author":"M Andrioli","year":"2006","unstructured":"Andrioli M, Pecori Giraldi F, Cavagnini F (2006) Isolated corticotrophin deficiency. Pituitary 9:289\u2013295","journal-title":"Pituitary"},{"key":"1141_CR56","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnz003","author":"M Yamamoto","year":"2020","unstructured":"Yamamoto M, Iguchi G, Bando H, Kanie K, Hidaka-Takeno R, Fukuoka H, Takahashi Y (2020) Autoimmune Pituitary Disease: New Concepts With Clinical Implications. Endocr Rev. https:\/\/doi.org\/10.1210\/endrev\/bnz003","journal-title":"Endocr Rev"},{"key":"1141_CR57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/0891693031000095871","volume":"36","author":"AA Kasperlik-Zaluska","year":"2003","unstructured":"Kasperlik-Zaluska AA, Czarnocka B, Czech W (2003) Autoimmunity as the most frequent cause of idiopathic secondary adrenal insufficiency: report of 111 cases. Autoimmunity 36:155\u2013159","journal-title":"Autoimmunity"},{"key":"1141_CR58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1507\/endocrj.EJ14-0369","volume":"62","author":"A Kiyota","year":"2015","unstructured":"Kiyota A, Iwama S, Sugimura Y, Takeuchi S, Takagi H, Iwata N, Nakashima K, Suzuki H, Nishioka T, Kato T, Enomoto A, Arima H, Kaibuchi K, Oiso Y (2015) Identification of the novel autoantigen candidate Rab GDP dissociation inhibitor alpha in isolated adrenocorticotropin deficiency. Endocr J 62:153\u2013160","journal-title":"Endocr J"},{"key":"1141_CR59","doi-asserted-by":"crossref","unstructured":"Fujita Y, Bando H, Iguchi G, Iida K, Shichi H, Kanie K, Matsumoto R, Suda K, Fukuoka H, Ogawa W, et al. (2019) SAT-LB079 Clinical Heterogeneity of Acquired Idiopathic ACTH Deficiency: A New Classification Based on the Clinical Characteristics and Autoantibodies. Journal of Endocrine Society 3","DOI":"10.1210\/js.2019-SAT-LB079"},{"key":"1141_CR60","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/cen.14082","volume":"91","author":"H Inaba","year":"2019","unstructured":"Inaba H, Ariyasu H, Iwakura H, Ueda Y, Kurimoto C, Uraki S, Takeshima K, Yamaoka H, Furukawa Y, Morita S, Nishi M, Akamizu T (2019) Comparative analysis of human leucocyte antigen between idiopathic and anti-PD-1 antibody induced isolated adrenocorticotropic hormone deficiency: A pilot study. Clin Endocrinol (Oxf) 91:786\u2013792","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1141_CR61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","volume":"130","author":"S Yano","year":"2020","unstructured":"Yano S, Ashida K, Sakamoto R, Sakaguchi C, Ogata M, Maruyama K, Sakamoto S, Ikeda M, Ohe K, Akasu S, Iwata S, Wada N, Matsuda Y, Nakanishi Y, Nomura M, Ogawa Y (2020) Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur J Cancer 130:198\u2013203","journal-title":"Eur J Cancer"},{"key":"1141_CR62","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11102-018-0901-7","volume":"21","author":"H Bando","year":"2018","unstructured":"Bando H, Iguchi G, Kanie K, Nishizawa H, Matsumoto R, Fujita Y, Odake Y, Yoshida K, Suda K, Fukuoka H, Tanaka K, Ogawa W, Takahashi Y (2018) Isolated adrenocorticotropic hormone deficiency as a form of paraneoplastic syndrome. Pituitary 21:480\u2013489","journal-title":"Pituitary"},{"key":"1141_CR63","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","volume":"86","author":"DL Morganstein","year":"2017","unstructured":"Morganstein DL, Lai Z, Spain L, Diem S, Levine D, Mace C, Gore M, Larkin J (2017) Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86:614\u2013620","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1141_CR64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583\u2013589","journal-title":"Ann Oncol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01141-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T11:58:30Z","timestamp":1625831910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01141-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01141-8","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"9 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors have no conflict of interest and financial support in relation to the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}